The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | ILyAD study: vitamin D supplementation in low tumor-burden indolent NHL treated with rituximab
Jonathan Friedberg, MD, MMSc, University of Rochester, Rochester, NY, provides an update on the ILyAD study (NCT03078855) – a double-blind, randomized trial which aimed to evaluate the effect of vitamin D (cholecalciferol) supplementation on disease outcomes in patients with low tumor-burden indolent non-Hodgkin lymphoma (NHL) treated with rituximab. There have been multiple reports of a significant association between low vitamin D levels at diagnosis and inferior overall survival. However, this study reported no statistically significant benefit of vitamin D supplementation on the outcomes of patients, suggesting that low vitamin D may be a surrogate for illness and comorbidity rather than a risk factor that can be addressed. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
